Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia

A prospective, multicenter study of 91 episodes

Robert R. Muder, Ann P. Harris, Sharon Muller, Michael Edmond, Joseph W. Chow, Konstantinos Papadakis, Marilyn W. Wagener, Gerald P. Bodey, James M. Steckelberg

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

We identified 91 cases of bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia in a prospective, multicenter observational study. The patients were highly compromised; the majority had an underlying malignancy, had received immunosuppressive therapy, and had indwelling venous catheters. Although 94% of patients received an antimicrobial agent to which the blood isolate was susceptible, the mortality among these patients 14 days after the onset of bacteremia was 21%. Mortality was significantly correlated with the presence of a hematologic malignancy or neutropenia or transplantation, immunosuppressive therapy, and a severity-of-illness score of >4. S. maltophilia infection is associated with substantial morbidity and mortality among highly compromised patients. The organism is typically resistant to expanded spectrum β-lactam agents and aminoglycoside antibiotics. Trimethoprim-sulfamethoxazole should be administered if the isolate is susceptible to this combination; addition of another agent to which the isolate is susceptible should be considered in treating patients who are neutropenic, immunocompromised, or critically ill.

Original languageEnglish (US)
Pages (from-to)508-512
Number of pages5
JournalClinical Infectious Diseases
Volume22
Issue number3
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Stenotrophomonas maltophilia
Bacteremia
Multicenter Studies
Prospective Studies
Immunosuppressive Agents
Mortality
Lactams
Indwelling Catheters
Sulfamethoxazole Drug Combination Trimethoprim
Aminoglycosides
Hematologic Neoplasms
Anti-Infective Agents
Neutropenia
Critical Illness
Observational Studies
Transplantation
Anti-Bacterial Agents
Morbidity
Therapeutics
Infection

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia : A prospective, multicenter study of 91 episodes. / Muder, Robert R.; Harris, Ann P.; Muller, Sharon; Edmond, Michael; Chow, Joseph W.; Papadakis, Konstantinos; Wagener, Marilyn W.; Bodey, Gerald P.; Steckelberg, James M.

In: Clinical Infectious Diseases, Vol. 22, No. 3, 01.01.1996, p. 508-512.

Research output: Contribution to journalArticle

Muder, RR, Harris, AP, Muller, S, Edmond, M, Chow, JW, Papadakis, K, Wagener, MW, Bodey, GP & Steckelberg, JM 1996, 'Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: A prospective, multicenter study of 91 episodes', Clinical Infectious Diseases, vol. 22, no. 3, pp. 508-512. https://doi.org/10.1093/clinids/22.3.508
Muder, Robert R. ; Harris, Ann P. ; Muller, Sharon ; Edmond, Michael ; Chow, Joseph W. ; Papadakis, Konstantinos ; Wagener, Marilyn W. ; Bodey, Gerald P. ; Steckelberg, James M. / Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia : A prospective, multicenter study of 91 episodes. In: Clinical Infectious Diseases. 1996 ; Vol. 22, No. 3. pp. 508-512.
@article{8c511175b63a4f37b227ec35d6752909,
title = "Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: A prospective, multicenter study of 91 episodes",
abstract = "We identified 91 cases of bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia in a prospective, multicenter observational study. The patients were highly compromised; the majority had an underlying malignancy, had received immunosuppressive therapy, and had indwelling venous catheters. Although 94{\%} of patients received an antimicrobial agent to which the blood isolate was susceptible, the mortality among these patients 14 days after the onset of bacteremia was 21{\%}. Mortality was significantly correlated with the presence of a hematologic malignancy or neutropenia or transplantation, immunosuppressive therapy, and a severity-of-illness score of >4. S. maltophilia infection is associated with substantial morbidity and mortality among highly compromised patients. The organism is typically resistant to expanded spectrum β-lactam agents and aminoglycoside antibiotics. Trimethoprim-sulfamethoxazole should be administered if the isolate is susceptible to this combination; addition of another agent to which the isolate is susceptible should be considered in treating patients who are neutropenic, immunocompromised, or critically ill.",
author = "Muder, {Robert R.} and Harris, {Ann P.} and Sharon Muller and Michael Edmond and Chow, {Joseph W.} and Konstantinos Papadakis and Wagener, {Marilyn W.} and Bodey, {Gerald P.} and Steckelberg, {James M.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1093/clinids/22.3.508",
language = "English (US)",
volume = "22",
pages = "508--512",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia

T2 - A prospective, multicenter study of 91 episodes

AU - Muder, Robert R.

AU - Harris, Ann P.

AU - Muller, Sharon

AU - Edmond, Michael

AU - Chow, Joseph W.

AU - Papadakis, Konstantinos

AU - Wagener, Marilyn W.

AU - Bodey, Gerald P.

AU - Steckelberg, James M.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - We identified 91 cases of bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia in a prospective, multicenter observational study. The patients were highly compromised; the majority had an underlying malignancy, had received immunosuppressive therapy, and had indwelling venous catheters. Although 94% of patients received an antimicrobial agent to which the blood isolate was susceptible, the mortality among these patients 14 days after the onset of bacteremia was 21%. Mortality was significantly correlated with the presence of a hematologic malignancy or neutropenia or transplantation, immunosuppressive therapy, and a severity-of-illness score of >4. S. maltophilia infection is associated with substantial morbidity and mortality among highly compromised patients. The organism is typically resistant to expanded spectrum β-lactam agents and aminoglycoside antibiotics. Trimethoprim-sulfamethoxazole should be administered if the isolate is susceptible to this combination; addition of another agent to which the isolate is susceptible should be considered in treating patients who are neutropenic, immunocompromised, or critically ill.

AB - We identified 91 cases of bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia in a prospective, multicenter observational study. The patients were highly compromised; the majority had an underlying malignancy, had received immunosuppressive therapy, and had indwelling venous catheters. Although 94% of patients received an antimicrobial agent to which the blood isolate was susceptible, the mortality among these patients 14 days after the onset of bacteremia was 21%. Mortality was significantly correlated with the presence of a hematologic malignancy or neutropenia or transplantation, immunosuppressive therapy, and a severity-of-illness score of >4. S. maltophilia infection is associated with substantial morbidity and mortality among highly compromised patients. The organism is typically resistant to expanded spectrum β-lactam agents and aminoglycoside antibiotics. Trimethoprim-sulfamethoxazole should be administered if the isolate is susceptible to this combination; addition of another agent to which the isolate is susceptible should be considered in treating patients who are neutropenic, immunocompromised, or critically ill.

UR - http://www.scopus.com/inward/record.url?scp=0029782406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029782406&partnerID=8YFLogxK

U2 - 10.1093/clinids/22.3.508

DO - 10.1093/clinids/22.3.508

M3 - Article

VL - 22

SP - 508

EP - 512

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -